Cargando…

Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines

BACKGROUND: The cell-surface attachment protein (Env) of the HERV-K(HML-2) lineage of endogenous retroviruses is a potentially attractive tumour-associated antigen for anti-cancer immunotherapy. The human genome contains around 100 integrated copies (called proviruses or loci) of the HERV-K(HML-2) v...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatkiewicz, Witold, Dickie, James, Bedford, Franchesca, Jones, Alexander, Atkin, Mark, Kiernan, Michele, Maze, Emmanuel Atangana, Agit, Bora, Farnham, Garry, Kanapin, Alexander, Belshaw, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007669/
https://www.ncbi.nlm.nih.gov/pubmed/32055257
http://dx.doi.org/10.1186/s13100-020-0204-1
_version_ 1783495352857395200
author Tatkiewicz, Witold
Dickie, James
Bedford, Franchesca
Jones, Alexander
Atkin, Mark
Kiernan, Michele
Maze, Emmanuel Atangana
Agit, Bora
Farnham, Garry
Kanapin, Alexander
Belshaw, Robert
author_facet Tatkiewicz, Witold
Dickie, James
Bedford, Franchesca
Jones, Alexander
Atkin, Mark
Kiernan, Michele
Maze, Emmanuel Atangana
Agit, Bora
Farnham, Garry
Kanapin, Alexander
Belshaw, Robert
author_sort Tatkiewicz, Witold
collection PubMed
description BACKGROUND: The cell-surface attachment protein (Env) of the HERV-K(HML-2) lineage of endogenous retroviruses is a potentially attractive tumour-associated antigen for anti-cancer immunotherapy. The human genome contains around 100 integrated copies (called proviruses or loci) of the HERV-K(HML-2) virus and we argue that it is important for therapy development to know which and how many of these contribute to protein expression, and how this varies across tissues. We measured relative provirus expression in HERV-K(HML-2), using enriched RNA-Seq analysis with both short- and long-read sequencing, in three Mantle Cell Lymphoma cell lines (JVM2, Granta519 and REC1). We also confirmed expression of the Env protein in two of our cell lines using Western blotting, and analysed provirus expression data from all other relevant published studies. RESULTS: Firstly, in both our and other reanalysed studies, approximately 10% of the transcripts mapping to HERV-K(HML-2) came from Env-encoding proviruses. Secondly, in one cell line the majority of the protein expression appears to come from one provirus (12q14.1). Thirdly, we find a strong tissue-specific pattern of provirus expression. CONCLUSIONS: A possible dependency of Env expression on a single provirus, combined with the earlier observation that this provirus is not present in all individuals and a general pattern of tissue-specific expression among proviruses, has serious implications for future HERV-K(HML-2)-targeted immunotherapy. Further research into HERV-K(HML-2) as a possible tumour-associated antigen in blood cancers requires a more targeted, proteome-based, screening protocol that will consider these polymorphisms within HERV-K(HML-2). We include a plan (and necessary alignments) for such work.
format Online
Article
Text
id pubmed-7007669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70076692020-02-13 Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines Tatkiewicz, Witold Dickie, James Bedford, Franchesca Jones, Alexander Atkin, Mark Kiernan, Michele Maze, Emmanuel Atangana Agit, Bora Farnham, Garry Kanapin, Alexander Belshaw, Robert Mob DNA Research BACKGROUND: The cell-surface attachment protein (Env) of the HERV-K(HML-2) lineage of endogenous retroviruses is a potentially attractive tumour-associated antigen for anti-cancer immunotherapy. The human genome contains around 100 integrated copies (called proviruses or loci) of the HERV-K(HML-2) virus and we argue that it is important for therapy development to know which and how many of these contribute to protein expression, and how this varies across tissues. We measured relative provirus expression in HERV-K(HML-2), using enriched RNA-Seq analysis with both short- and long-read sequencing, in three Mantle Cell Lymphoma cell lines (JVM2, Granta519 and REC1). We also confirmed expression of the Env protein in two of our cell lines using Western blotting, and analysed provirus expression data from all other relevant published studies. RESULTS: Firstly, in both our and other reanalysed studies, approximately 10% of the transcripts mapping to HERV-K(HML-2) came from Env-encoding proviruses. Secondly, in one cell line the majority of the protein expression appears to come from one provirus (12q14.1). Thirdly, we find a strong tissue-specific pattern of provirus expression. CONCLUSIONS: A possible dependency of Env expression on a single provirus, combined with the earlier observation that this provirus is not present in all individuals and a general pattern of tissue-specific expression among proviruses, has serious implications for future HERV-K(HML-2)-targeted immunotherapy. Further research into HERV-K(HML-2) as a possible tumour-associated antigen in blood cancers requires a more targeted, proteome-based, screening protocol that will consider these polymorphisms within HERV-K(HML-2). We include a plan (and necessary alignments) for such work. BioMed Central 2020-02-07 /pmc/articles/PMC7007669/ /pubmed/32055257 http://dx.doi.org/10.1186/s13100-020-0204-1 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tatkiewicz, Witold
Dickie, James
Bedford, Franchesca
Jones, Alexander
Atkin, Mark
Kiernan, Michele
Maze, Emmanuel Atangana
Agit, Bora
Farnham, Garry
Kanapin, Alexander
Belshaw, Robert
Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
title Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
title_full Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
title_fullStr Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
title_full_unstemmed Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
title_short Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
title_sort characterising a human endogenous retrovirus(herv)-derived tumour-associated antigen: enriched rna-seq analysis of herv-k(hml-2) in mantle cell lymphoma cell lines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007669/
https://www.ncbi.nlm.nih.gov/pubmed/32055257
http://dx.doi.org/10.1186/s13100-020-0204-1
work_keys_str_mv AT tatkiewiczwitold characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT dickiejames characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT bedfordfranchesca characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT jonesalexander characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT atkinmark characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT kiernanmichele characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT mazeemmanuelatangana characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT agitbora characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT farnhamgarry characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT kanapinalexander characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines
AT belshawrobert characterisingahumanendogenousretrovirushervderivedtumourassociatedantigenenrichedrnaseqanalysisofhervkhml2inmantlecelllymphomacelllines